Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung
Open accessAbstract
Invasive aspergillosis (IA) remains the primary cause of morbidity and mortality in chronic granulomatous disease (CGD) patients, often due to infection by Aspergillus species refractory to antifungals. This motivates the search for alternative treatments, including immunotherapy. We investigated the effect of exogenous type I interferon (IFN) activation on the outcome of IA caused by three Aspergillus species, A. fumigatus , A. nidulans , and A. tanneri , in CGD mice. The animals were treated with poly(I):poly(C) carboxymethyl cellulose poly- l -lysine (PICLC), a mimetic of double-stranded RNA, 24 h preinfection and postinfection. The survival rates and lung fungal burdens were markedly improved by PICLC immunotherapy in animals infected with any one of the three Aspergillus species. While protection from IA was remarkable, PICLC induction of type I IFN in the lungs surged 24 h posttreatment and returned to baseline levels by 48 h, suggesting that PICLC altered early events in protection against IA. Immunophenotyping of recruited leukocytes and histopathological examination of tissue sections showed that PICLC induced similar cellular infiltrates as those in untreated-infected mice, in both cases dominated by monocytic cells and neutrophils. However, the PICLC immunotherapy resulted in a marked earlier recruitment of the leukocytes. Unlike with conidia, infection with A. nidulans germlings reduced the protective effect of PICLC immunotherapy. Additionally, antibody depletion of neutrophils totally reversed the protection, suggesting that neutrophils are crucial for PICLC-mediated protection. Together, these data show that prophylactic PICLC immunotherapy prerecruits these cells, enabling them to attack the conidia and thus resulting in a profound protection from IA. IMPORTANCE Patients with chronic granulomatous disease (CGD) are highly susceptible to invasive aspergillosis (IA). While Aspergillus fumigatus is the most-studied Aspergillus species, CGD patients often suffer IA caused by A. nidulans , A. tanneri , and other rare species. These non- fumigatus Aspergillus species are more resistant to antifungal drugs and cause higher fatality rates than A. fumigatus . Therefore, alternative therapies are needed to protect CGD patients. We report an effective immunotherapy of mice infected with three Aspergillus species via PICLC dosing. While protection from IA was long lasting, PICLC induction of type I IFN surged but quickly returned to baseline levels, suggesting that PICLC was altering early events in IA. Interestingly, we found responding immune cells to be similar between PICLC-treated and untreated-infected mice. However, PICLC immunotherapy resulted in an earlier recruitment of the leukocytes and suppressed fungal growth. This study highlights the value of type I IFN induction in CGD patients.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CCR2+ inflammatory monocytes are required for initiating a coordinated type I and type III interferon signaling pathway that is critical for optimal ROS production by neutrophils.
“In particular, CCR2+ inflammatory monocytes are required for initiating a coordinated type I and type III interferon signaling pathway that is critical for optimal ROS production by neutrophils (196, 273).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [273]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199 · see citing works
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · see citing works
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · see citing works
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · see citing works
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,768 · see citing works
Pollock, J. D., Williams, D. A., Gifford, M. A. C., Li, L. L., Du, X., Fisherman, J., Orkin, S. H., Doerschuk, C. M., & Dinauer, M. C. (1995) · Nature Genetics · doi:10.1038/ng0295-202 · Cited by 921 · see citing works
Genetic, Biochemical, and Clinical Features of Chronic Granulomatous Disease
Segal, B. H., Leto, T. L., Gallin, J. I., Malech, H. L., & Holland, S. M. (2000) · Medicine · doi:10.1097/00005792-200005000-00004 · Cited by 877 · see citing works
A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease
The International Chronic Granulomatous Disease Cooperative Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199102213240801 · Cited by 830 · see citing works
Type I IFN s induce anti‐tumor polarization of tumor associated neutrophils in mice and human
Andzinski, L., Kasnitz, N., Stahnke, S., Wu, C., Gereke, M., von Köckritz‐Blickwede, M., Schilling, B., Brandau, S., Weiß, S., & Jabłońska, J. (2015) · International Journal of Cancer · doi:10.1002/ijc.29945 · Cited by 433 · see citing works
Itraconazole to Prevent Fungal Infections in Chronic Granulomatous Disease
Gallin, J. I., Alling, D. W., Malech, H. L., WESLEY, R. A., Koziol, D. E., Marciano, B. E., Eisenstein, E. M., Turner, M. L. C., DeCarlo, E. S., Starling, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021931 · Cited by 394 · see citing works
Diefenbach, A., Schindler, H., Donhauser, N., Lorenz, E., Laskay, T., MacMicking, J. D., Röllinghoff, M., Gresser, I., & Bogdan, C. (1998) · Immunity · doi:10.1016/s1074-7613(00)80460-4 · Cited by 368 · see citing works
Twelve immunotherapy drugs that could cure cancers
Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 339 · see citing works
Martinelli, S., Urosevic, M., Daryadel, A., Oberholzer, P. A., Baumann, C. K., Fey, M. F., Dummer, R., Simon, H., & Yousefi, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405883200 · Cited by 294 · see citing works
Phagocytosis and Intracellular Fate of<i>Aspergillus fumigatus</i>Conidia in Alveolar Macrophages
Ibrahim-Granet, O., Philippe, B., Boleti, H., Boisvieux-Ulrich, E., Grenet, D., Stern, M., & Latgé, J. P. (2003) · Infection and Immunity · doi:10.1128/iai.71.2.891-903.2003 · Cited by 277 · see citing works
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series
Delsing, C. E., Gresnigt, M. S., Leentjens, J., Preijers, F. W. M. B., Allantaz, F., Kox, M., Monneret, G., Venet, F., Bleeker‐Rovers, C. P., van de Veerdonk, F. L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-166 · Cited by 273 · see citing works
A Modified Polyriboinosinic-Polyribocytidylic Acid Complex That Induces Interferon in Primates
Levy, H. B., Baer, G. Μ., Baron, S., Buckler, C. E., Gibbs, C. J., Iadarola, M. J., London, W. T., & Rice, J. M. (1975) · The Journal of Infectious Diseases · doi:10.1093/infdis/132.4.434 · Cited by 270 · see citing works
Aspergillus nidulans Infection in Chronic Granulomatous Disease
Segal, B. H., DeCarlo, E. S., Kwon-Chung, K. J., Malech, H. L., Gallin, J. I., & Holland, S. M. (1998) · Medicine · doi:10.1097/00005792-199809000-00004 · Cited by 263 · see citing works
Self-citationViral tricks to grid-lock the type I interferon system
Versteeg, G. A., & García‐Sastre, A. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.05.009 · Cited by 256 · see citing works
Type I IFN Signaling Is Crucial for Host Resistance against Different Species of Pathogenic Bacteria
Mancuso, G., Midiri, A., Biondo, C., Beninati, C., Zummo, S., Galbo, R., Tomasello, F. F., Gambuzza, M. E., Macrì, G., Ruggeri, A., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3126 · Cited by 248 · see citing works
In Vivo Bronchoalveolar Macrophage Defense Against Rhizopus oryzae and Aspergillus fumigatus
Waldorf, A. R., Levitz, S. M., & Diamond, R. D. (1984) · The Journal of Infectious Diseases · doi:10.1093/infdis/150.5.752 · Cited by 247 · see citing works
Innate Immunity toAspergillusSpecies
Park, S. J., & Mehrad, B. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-09 · Cited by 230 · see citing works
Efficacy of a Technique for Exposing the Mouse Lung to Particles Aspirated from the Pharynx
Rao, G. V. S., Tinkle, S. S., Weissman, D. N., Antonini, J. M., Kashon, M. L., Salmen, R., Battelli, L. A., Willard, P. A., Hubbs, A. F., & Hoover, M. D. (2003) · Journal of Toxicology and Environmental Health · doi:10.1080/15287390306417 · Cited by 216 · see citing works
del Fresno, C., Soulat, D., Roth, S., Blazek, K. D., Udalova, I. A., Sancho, D., Ruland, J., & Ardavı́n, C. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.010 · Cited by 189 · see citing works
Gazendam, R. P., van Hamme, J. L., Tool, A. T. J., Hoogenboezem, M., van den Berg, J. M., Prins, J. M., Vitkov, L., van de Veerdonk, F. L., van den Berg, T. K., Roos, D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501811 · Cited by 187 · see citing works
Zarember, K. A., Sugui, J. A., Chang, Y. C., Kwon-Chung, K. J., & Gallin, J. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6367 · Cited by 184 · see citing works
Self-citationPoly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs
Ammi, R., Waele, J. D., Willemen, Y., Brussel, I. V., Schrijvers, D. M., Lion, E., & Smits, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.09.010 · Cited by 175 · see citing works
Bonnett, C. R., Cornish, E. J., Harmsen, A. G., & Burritt, J. B. (2006) · Infection and Immunity · doi:10.1128/iai.00909-06 · Cited by 174 · see citing works
Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors
Otten, M. A., Rudolph, E., Dechant, M., Tuk, C. W., Reijmers, R. M., Beelen, R. H. J., van de Winkel, J. G. J., & van Egmond, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5472 · Cited by 152 · see citing works
The innate immune response to Aspergillus fumigatus at the alveolar surface
Margalit, A., & Kavanagh, K. A. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv018 · Cited by 129 · see citing works
Salazar, A. Μ., Erlich, R. B., Mark, A. S., Bhardwaj, N., & Herberman, R. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0024 · Cited by 122 · see citing works
Self-citationBourgeois, C., Majer, O., Frohner, I. E., Lesiak-Markowicz, I., Hildering, K.-S., Glaser, W., Stockinger, S., Decker, T., Akira, S., Müller, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002599 · Cited by 116 · see citing works
Invasive Aspergillosis Due toNeosartorya udagawae
Vinh, D. C., M.S., Y. R. S., Sugui, J. A., Castellar, E. R. P., Freeman, A. F., Campbell, J. W., Pittaluga, S., Jones, P. A., Zelazny, A. M., Kleiner, D. E., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/599345 · Cited by 109 · see citing works
Self-citationInvasive aspergillosis in chronic granulomatous disease
Segal, B. H., & Romani, L. R. (2009) · Medical Mycology · doi:10.1080/13693780902736620 · Cited by 108 · see citing works
Epidemiology and Outcome of Invasive Fungal Diseases in Patients With Chronic Granulomatous Disease
Beauté, J., Obenga, G., Mignot, L. L., Mahlaoui, N., Bougnoux, M., Mouy, R., Gougerot‐Pocidalo, M., Barlogis, V., Suárez, F., Lanternier, F., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181f13b23 · Cited by 105 · see citing works
Moreira-Teixeira, L., Sousa, J., McNab, F. W., Torrado, E., Cardoso, F., Machado, H., Castro, F., Cardoso, V., Gaifem, J., Wu, X., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600584 · Cited by 99 · see citing works
Invasive aspergillosis in primary immunodeficiencies
Almyroudis, N. G., Holland, S. M., & Segal, B. H. (2005) · Medical Mycology · doi:10.1080/13693780400025203 · Cited by 91 · see citing works
Cryptococcus neoformans–Induced Macrophage Lysosome Damage Crucially Contributes to Fungal Virulence
Davis, M. J., Eastman, A. J., Qiu, Y., Gregorka, B., Kozel, T. R., Osterholzer, J. J., Curtis, J. L., Swanson, J. A., & Olszewski, M. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402376 · Cited by 80 · see citing works
Self-citationSugui, J. A., Peterson, S. W., Abigail, F., Hansen, B. T., Samson, R. A., Mellado, E., Cuenca‐Estrella, M., & Kwon-Chung, K. J. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01704-14 · Cited by 80 · see citing works
Self-citationHubka, V., Kubátová, A., Mallátová, N., Sedlacek, P., Melichar, J., Skořepová, M., Mencl, K., Lysková, P., Sramkova, B., Chudíčková, M., et al. (2012) · Medical Mycology · doi:10.3109/13693786.2012.667578 · Cited by 79 · see citing works
Aspergillosis in Chronic Granulomatous Disease
King, J., Henriet, S., & Warris, A. (2016) · Journal of Fungi · doi:10.3390/jof2020015 · Cited by 76 · see citing works
Role of Neutrophils in Invasive Aspergillosis ▿
Feldmesser, M. (2006) · Infection and Immunity · doi:10.1128/iai.01551-06 · Cited by 57 · see citing works
Chronic Invasive Aspergillosis caused byAspergillus viridinutans
Vinh, D. C., M.S., Y. R. S., Jones, P. A., Freeman, A. F., Zelazny, A. M., & Holland, S. M. (2009) · Emerging infectious diseases · doi:10.3201/eid1508.090251 · Cited by 56 · see citing works
Biondo, C., Midiri, A., Gambuzza, M. E., Gerace, E., Falduto, M. L., Galbo, R., Bellantoni, A., Beninati, C., Teti, G., Leanderson, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.566 · Cited by 54 · see citing works
PRIMARY PHAGOCYTIC DISORDERS OF CHILDHOOD
Segal, B. H., & Holland, S. M. (2000) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70273-x · Cited by 54 · see citing works
Sugui, J. A., Peterson, S. W., Clark, L. P., Nardone, G. A., Folio, L. R., Riedlinger, G., Zerbe, C. S., M.S., Y. R. S., Henderson, C. M., Zelazny, A. M., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01509-12 · Cited by 51 · see citing works
Self-citationUne, C., Andersson, J., & Örn, A. (2003) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2003.02294.x · Cited by 49 · see citing works
Åhlin, A., Elinder, G., & Palmblad, J. E. W. (1997) · Blood · doi:10.1182/blood.v89.9.3396 · Cited by 42 · see citing works
Inglis, D. O., Berkes, C. A., Murray, D. H., & Sil, A. (2010) · Infection and Immunity · doi:10.1128/iai.00204-10 · Cited by 40 · see citing works
Immunotherapy in Invasive Fungal Infection - Focus on Invasive Aspergillosis
Lehrnbecher, T., Kalkum, M., Champer, J., Tramsen, L., Schmidt, S., & Klingebiel, T. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319200010 · Cited by 37 · see citing works
Type I IFN Induction via Poly-ICLC Protects Mice against Cryptococcosis
Sionov, E., Mayer-Barber, K. D., Chang, Y. C., Kauffman, K. D., Eckhaus, M., Salazar, A. Μ., Barber, D. L., & Kwon-Chung, K. J. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005040 · Cited by 33 · see citing works
Self-citationImmunotherapy of aspergillosis
Carvalho, A., Cunha, C., Bistoni, F., & Romani, L. R. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03681.x · Cited by 33 · see citing works
Real-time visualization of immune cell clearance of Aspergillus fumigatus spores and hyphae
Knox, B. P., Anna Huttenlocher, A., & Keller, N. P. (2017) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2017.05.005 · Cited by 26 · see citing works
Levy, H. B., Riley, F. L., Lvovsky, E., et al. (1981) · Infection and Immunity · doi:10.1128/iai.34.2.416-421.1981 · Cited by 20 · see citing works
Seyedmousavi, S., & Verweij, P. E. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_22 · Cited by 8 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400 · see citing works
Seyedmousavi, S., Chang, Y. C., Law, D., Birch, M., Rex, J. H., & Kwon-Chung, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00129-19 · Cited by 56 · see citing works
Self-citationRiedelberger, M., Penninger, P., Tscherner, M., Hadriga, B., Brunnhofer, C., Jenull, S., Stoiber, A., Bourgeois, C., Petryshyn, A., Glaser, W., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101121 · Cited by 23 · see citing works
Type I interferons during host–fungus interactions: Is antifungal immunity going viral?
Pekmezovic, M., Dietschmann, A., & Gresnigt, M. S. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010740 · Cited by 12 · see citing works
- Authors
- Seyedmousavi, S., Davis, M. J., Sugui, J. A., Pinkhasov, T., Moyer, S., Salazar, A. M., Chang, Y. C., & Kwon-Chung, K. J.
- Affiliations
- National Institutes of Health (US)
- Oncovir Inc., Washington, DC, USA
- Corresponding author
- Kwon-Chung, Kyung J.
- Venue
- mBio
- Publisher
- American Society for Microbiology
- Published
- 2018-05-02
- Volume
- 9
- Issue
- 2
- ISSN
- 2150-7511 (ISSN-L)
- 2161-2129
- PMC
- PMC5874922
- OpenAlex
- W2791402554
- Cited by
- 17
- References
- 54
- Citations by year
- 2026: 2 · 2025: 2 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 4
- FWCI
- 1.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- mBio (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Immunology and Microbiology › Immunology › Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Keywords
- chronic granulomatous disease, type I interferon, double-stranded RNA, neutrophil recruitment, Aspergillus fumigatus, Aspergillus nidulans, immunotherapy, neutrophils, antifungal resistance, prophylaxis
- MeSH terms
- Animals, Antifungal Agents, Aspergillosis, Aspergillus, Flow Cytometry, Granulomatous Disease, Chronic, Interferon Type I, Lung, Male, Neutrophils, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
